Relmada Therapeutics, a clinical-stage biotechnology company, shared a transformative update in a recent letter to shareholders.
The company highlighted strategic reviews, portfolio expansion, and promising developments in their key product candidates.
Noteworthy additions to the portfolio include NDV-01 for bladder cancer and Sepranolone for compulsivity disorders.
NDV-01 Phase 2 Results
Impressive 91% complete response rate in bladder cancer study.
Strategic Team Additions
Recruitment of experts in bladder cancer to support NDV-01 development.
Sepranolone Progress
Advancing towards a Phase 2 study for Prader-Willi Syndrome in 2026.
Upcoming Milestones
Including Phase 3 trial initiation for NDV-01 and FDA engagement for Sepranolone.
- Relmada's key product candidates show significant potential in addressing unmet medical needs in oncology and central nervous system disorders.
- The positive results and strategic additions position the company for value creation through disciplined execution and focused development.
Relmada Therapeutics remains optimistic about its future, fueled by the progress of NDV-01 and Sepranolone, alongside a strengthened team.